China's NMPA grants CanSino Biologics approval for clinical trials of recombinant trivalent poliomyelitis vaccine

CanSino Biologics, Inc. Class H ( 6185 -2.44% ▼ ) has issued an announcement.

CanSino Biologics Inc. has received approval from the National Medical Products Administration of China to conduct clinical trials for its Recombinant Trivalent Poliomyelitis Vaccine. This vaccine, which does not contain viral genetic material and is produced without using live viruses, is expected to have strong safety and immunogenicity profiles. The World Health Organization recommends non-infectious polio VLP-based vaccines, like CanSino’s, as a preferred option for future polio prevention, potentially positioning the company as a key player in the post-eradication polio vaccine market.

More about CanSino Biologics, Inc. Class H

CanSino Biologics Inc. is a biotechnology company based in China, focusing on the development and production of innovative vaccines. The company is involved in creating vaccines using advanced technologies, such as protein structure design and virus-like particle assembly, with a market focus on addressing global health challenges.

Original links: CanSino Biologics Gains Approval for Polio Vaccine Clinical Trials in China - TipRanks.com